Dianthus Therapeutics
DNTH
30 hedge funds and large institutions have $136M invested in Dianthus Therapeutics in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 25 closing their positions.
3,383% more capital inflows, than outflows
Capital inflows: $107M | Capital outflows: $3.08M
20.14% more ownership
Funds ownership: 47.87% → 68.01% (+20%)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
35% less funds holding
Funds holding: 46 → 30 (-16)
64% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.9M |
| 2 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$24.3M |
| 3 |
5VM
5AM Venture Management
San Francisco,
California
|
+$18.5M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$15.3M |
| 5 |
VA
VR Adviser
New York
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.32M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
-$287K |
| 3 |
Harvard Management Company
Boston,
Massachusetts
|
-$252K |
| 4 |
Leonteq Securities AG
Zurich,
Switzerland
|
-$152K |
| 5 |
Two Sigma Advisers
New York
|
-$134K |
DNTH Hedge Fund Activity: Q3 2023 in Review
30 of the 6,314 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q3 2023, worth a combined $136M — up 519% from $22M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of DNTH and 9 opened new positions — a net loss of 16 holders — while 10 trimmed existing stakes and 9 added.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $27.9M. The largest seller was Citadel Advisors, cutting an estimated $1.32M.
- 30 institutional investors held Dianthus Therapeutics (DNTH) as of Q3 2023, down from 46 in Q2 2023.
- Funds reported $136M of Dianthus Therapeutics stock for Q3 2023, up 519% quarter-over-quarter.
- 9 funds opened new Dianthus Therapeutics positions in Q3 2023 and 25 closed out, a net change of -16 holders.
- The largest Dianthus Therapeutics buyer in Q3 2023 was Fidelity Investments, an estimated $27.9M added.
- The largest Dianthus Therapeutics seller in Q3 2023 was Citadel Advisors, an estimated $1.32M sold.
Based on aggregated 13F filings for Q3 2023.